We serve Chemical Name:Bisnorargemonine CAS:301207-46-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Bisnorargemonine
CAS.NO:301207-46-5
Synonyms:Argemonine,O9-didemethyl
Molecular Formula:C14H14N2O2
Molecular Weight:242.27300
HS Code:2924299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:361.1ºC at 760 mmHg
Density:1.245g/cm3
Index of Refraction:1.658
PSA:64.35000
Exact Mass:242.10600
LogP:3.18390
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Argemonine,O9-didemethyl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Argemonine,O9-didemethyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Argemonine,O9-didemethyl Use and application,Argemonine,O9-didemethyl technical grade,usp/ep/jp grade.
Related News: Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue. Bisnorargemonine manufacturer Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs. Bisnorargemonine supplier From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. Bisnorargemonine vendor From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. Bisnorargemonine factory Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations.
